Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer
China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US...
Clinical trial approval / initiation
Sichuan Biokin’s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma
China’s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study
Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...
InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical trial...
Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC
China-based Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566) announced that it has received clinical approval...
Fosun Pharmaceutical Launches Phase III Study for Fumaining in Pediatric Low-Grade Glioma
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the initiation of a...
Zhimeng Biopharma’s CB03-154 Receives CDE Approval for ALS Phase II/III Clinical Study
China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II/III clinical study...
HKYM Biopharma’s KM1 Receives NMPA Green-Light for Phase Ib/II Study in Advanced Solid Tumors
Shenzhen-based oncolytic virus specialist HKYM Biopharma has announced receiving the green-light from the National Medical...
United Laboratories Receives FDA Approval for Clinical Study of UBT37034 in Overweight/Obesity Treatment
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that it has received...
Hengrui Pharmaceuticals Receives NMPA Clearance for SHR-2173 in Primary Membranous Nephropathy
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...
Jiangsu Hengrui Gains NMPA Clinical Clearance for HRS-9821 in COPD Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema
German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...
Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that it has received clinical approval...
SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study
China’s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG...
Akeso Biopharma Initiates Phase Ia Clinical Study for Trop2/Nectin4 Bispecific ADC AK146D1
China-based Akeso Biopharma (HKG: 9926) announced the initiation of a Phase Ia clinical study for...
Jiangsu Kanion Receives NMPA Approval for KYS2301 Gel in Atopic Dermatitis Clinical Study
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) announced that it has received approval from...
CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...
Genrix Bio Receives NMPA Clearance for GR1803 in Relapsed/Refractory Multiple Myeloma
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that it has received clinical trial...
China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...
InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...